MUMBAI, India, June 2, 2026
Alkem Laboratories has announced the launch of India’s first semaglutide single-shot pre-filled syringes, marking a significant advancement in the accessibility of GLP-1-based therapies for the management of Type 2 diabetes and obesity. Priced from INR 350, the new formulation is designed to lower entry barriers for patients requiring long-term metabolic disease treatment while expanding delivery options beyond conventional injection pens. The launch follows approval from the Drugs Controller General of India (DCGI) and strengthens Alkem’s growing presence in the rapidly evolving diabetes and obesity treatment market. With metabolic disorders continuing to rise across India, the introduction of a convenient and affordable semaglutide delivery format is expected to support broader adoption of one of the most effective therapeutic classes for glycemic control and weight management. The move also reinforces Alkem’s strategy of improving patient access through innovation, affordability, and diversified drug delivery solutions.
Alkem Expands Access to Semaglutide Therapy in India
The newly launched single-shot pre-filled syringe format offers a ready-to-use administration option that enhances convenience for both physicians and patients. Alkem becomes the first pharmaceutical company in India to introduce semaglutide in this delivery format, creating additional flexibility for treatment selection while helping reduce cost-related barriers. Semaglutide, a GLP-1 receptor agonist, has transformed the management of Type 2 diabetes and obesity globally due to its proven ability to improve blood glucose control and support significant weight reduction. By introducing a lower-cost format with pricing beginning at INR 350, Alkem aims to increase accessibility to a larger patient population.
The company had previously launched semaglutide in pre-filled disposable and reusable injection pens in March 2026 and has also secured regulatory approval for semaglutide vial presentations that are expected to be introduced in the near future. This multi-format strategy reflects a growing focus on patient-centered care and treatment adherence in chronic disease management.
Growing Demand for Diabetes and Obesity Treatments
Advertisement
India continues to face a significant and growing burden of metabolic disorders, with rising rates of Type 2 diabetes, obesity, and associated cardiovascular complications. Healthcare providers increasingly recognize the importance of therapies that address both glycemic control and weight management simultaneously. Semaglutide has emerged as one of the most impactful therapeutic options in this category due to its ability to target key metabolic pathways involved in appetite regulation and insulin sensitivity. By broadening the availability of semaglutide through multiple delivery systems, Alkem is helping address practical challenges that may prevent patients from initiating or continuing therapy.
Company leadership emphasized that offering diverse administration formats allows physicians to tailor treatment choices to individual patient needs, ultimately supporting improved clinical outcomes and long-term disease management. The launch also highlights the increasing adoption of advanced biologic and peptide-based therapies within the Indian pharmaceutical market.
Strengthening Alkem’s Position in Metabolic Healthcare
The launch of semaglutide pre-filled syringes further strengthens Alkem’s position within chronic therapy segments, including diabetes, cardiology, neurology, and related metabolic disorders. As one of India’s leading pharmaceutical companies, Alkem continues to invest in expanding access to high-quality and affordable medicines while leveraging its manufacturing and research capabilities to support innovation. The company’s decision to rapidly introduce multiple semaglutide formats reflects confidence in the long-term growth potential of obesity and diabetes therapies, which remain among the most dynamic sectors in global healthcare.
With regulatory approvals already secured and additional product launches planned, Alkem is positioning itself to play a significant role in meeting the growing demand for effective metabolic disease treatments. The introduction of India’s first semaglutide single-shot pre-filled syringe not only represents a commercial milestone but also underscores the importance of improving access to modern therapies for millions of patients living with chronic metabolic conditions.
Source: Alkem Laboratories press release
